SG11201600055PA - Protein tyrosine kinase modulators and methods of use - Google Patents
Protein tyrosine kinase modulators and methods of useInfo
- Publication number
- SG11201600055PA SG11201600055PA SG11201600055PA SG11201600055PA SG11201600055PA SG 11201600055P A SG11201600055P A SG 11201600055PA SG 11201600055P A SG11201600055P A SG 11201600055PA SG 11201600055P A SG11201600055P A SG 11201600055PA SG 11201600055P A SG11201600055P A SG 11201600055PA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- tyrosine kinase
- protein tyrosine
- kinase modulators
- modulators
- Prior art date
Links
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013079232 | 2013-07-11 | ||
| PCT/CN2014/082084 WO2015003658A1 (en) | 2013-07-11 | 2014-07-11 | Protein tyrosine kinase modulators and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201600055PA true SG11201600055PA (en) | 2016-02-26 |
Family
ID=52279364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600055PA SG11201600055PA (en) | 2013-07-11 | 2014-07-11 | Protein tyrosine kinase modulators and methods of use |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9783524B2 (https=) |
| EP (1) | EP3019489A4 (https=) |
| JP (1) | JP6510510B2 (https=) |
| AU (1) | AU2014289762B2 (https=) |
| CA (1) | CA2917735C (https=) |
| RU (1) | RU2656591C2 (https=) |
| SG (1) | SG11201600055PA (https=) |
| TW (1) | TWI610923B (https=) |
| WO (1) | WO2015003658A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033941A1 (en) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| MY169791A (en) | 2008-10-22 | 2019-05-15 | Array Biopharma Inc | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| ME03376B (me) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| CN113354649B (zh) | 2014-11-16 | 2024-12-10 | 阵列生物制药公司 | 一种新的晶型 |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| CN104803925B (zh) * | 2015-04-16 | 2018-01-12 | 温州医科大学 | 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途 |
| CA2984586C (en) * | 2015-04-29 | 2021-02-16 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor |
| CN106187915A (zh) * | 2015-05-27 | 2016-12-07 | 上海翰森生物医药科技有限公司 | 具有alk与egfr双重活性的抑制剂及其制备方法和应用 |
| CN105017160B (zh) * | 2015-06-24 | 2017-12-29 | 温州医科大学 | 一种嘧啶类egfrt790m抑制剂及其合成方法和应用 |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| CN106749267B (zh) * | 2015-11-23 | 2020-08-21 | 南京圣和药业股份有限公司 | 新的表皮生长因子受体抑制剂及其应用 |
| CN106883213B (zh) * | 2015-12-15 | 2021-04-20 | 合肥中科普瑞昇生物医药科技有限公司 | 一种egfr和alk激酶的双重抑制剂 |
| CN106928150B (zh) * | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技（上海）有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| FI3439662T3 (fi) | 2016-04-04 | 2024-09-04 | Loxo Oncology Inc | (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita |
| EP3458456B1 (en) | 2016-05-18 | 2020-11-25 | Loxo Oncology Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| WO2018019252A1 (en) * | 2016-07-26 | 2018-02-01 | Jacobio Pharmaceuticals Co., Ltd. | Novel fused pyridine derivatives useful as fak/aurora kinase inhibitors |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI798334B (zh) * | 2018-01-31 | 2023-04-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｅｒｂｂ／ｂｔｋ抑制劑 |
| CN110372664A (zh) * | 2018-04-13 | 2019-10-25 | 华东理工大学 | 选择性jak2抑制剂及其应用 |
| US10644385B1 (en) * | 2019-03-14 | 2020-05-05 | L3Harris Technologies, Inc. | Wideband antenna system components in rotary aircraft rotors |
| CN113544130B (zh) | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| KR102168179B1 (ko) * | 2019-10-31 | 2020-10-20 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
| WO2021142408A1 (en) | 2020-01-11 | 2021-07-15 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Estrogen metabolite levels and cancer driver gene mutations in lung cancer risk stratification and treatment |
| WO2022042755A1 (zh) * | 2020-08-28 | 2022-03-03 | 华东理工大学 | 抑制突变型egfr的化合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PT1660458E (pt) * | 2003-08-15 | 2012-04-27 | Novartis Ag | 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário |
| EA017405B9 (ru) * | 2006-12-08 | 2014-05-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| US7834024B2 (en) * | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| WO2011140338A1 (en) * | 2010-05-05 | 2011-11-10 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| RS54189B1 (sr) * | 2011-02-02 | 2015-12-31 | Novartis Ag | Postupci za korišćenje inibitora alk |
-
2014
- 2014-07-11 EP EP14822363.9A patent/EP3019489A4/en not_active Withdrawn
- 2014-07-11 RU RU2016103938A patent/RU2656591C2/ru active
- 2014-07-11 JP JP2016524675A patent/JP6510510B2/ja not_active Expired - Fee Related
- 2014-07-11 US US14/903,369 patent/US9783524B2/en not_active Expired - Fee Related
- 2014-07-11 CA CA2917735A patent/CA2917735C/en not_active Expired - Fee Related
- 2014-07-11 TW TW103124057A patent/TWI610923B/zh not_active IP Right Cessation
- 2014-07-11 AU AU2014289762A patent/AU2014289762B2/en not_active Ceased
- 2014-07-11 SG SG11201600055PA patent/SG11201600055PA/en unknown
- 2014-07-11 WO PCT/CN2014/082084 patent/WO2015003658A1/en not_active Ceased
-
2017
- 2017-09-01 US US15/694,620 patent/US10059688B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1221953A1 (zh) | 2017-06-16 |
| US10059688B2 (en) | 2018-08-28 |
| CA2917735A1 (en) | 2015-01-15 |
| CA2917735C (en) | 2017-04-18 |
| TW201512176A (zh) | 2015-04-01 |
| WO2015003658A1 (en) | 2015-01-15 |
| RU2016103938A (ru) | 2017-08-16 |
| US20160145237A1 (en) | 2016-05-26 |
| TWI610923B (zh) | 2018-01-11 |
| EP3019489A1 (en) | 2016-05-18 |
| US20180009782A1 (en) | 2018-01-11 |
| AU2014289762A1 (en) | 2016-02-18 |
| US9783524B2 (en) | 2017-10-10 |
| JP6510510B2 (ja) | 2019-05-08 |
| AU2014289762B2 (en) | 2017-02-16 |
| JP2016525509A (ja) | 2016-08-25 |
| RU2656591C2 (ru) | 2018-06-06 |
| EP3019489A4 (en) | 2016-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201600055PA (en) | Protein tyrosine kinase modulators and methods of use | |
| IL290547A (en) | Antibodies and methods of use | |
| IL280155A (en) | Anti- SIGLEC-8 antibodies and methods of using them | |
| IL244495B (en) | Anti-alpha-synuclein antibodies and methods of use | |
| IL240818A0 (en) | Combinations of proton tyrosine kinase inhibitors and 4a3cyp inhibitors | |
| ZA201603308B (en) | Novel anti-claudin antibodies and methods of use | |
| IL245946A0 (en) | Anti-dpep3 antibodies and methods of use | |
| SG11201601416VA (en) | Novel sez6 modulators and methods of use | |
| IL250318B (en) | Protein kinase c inhibitors and methods of using them | |
| IL244643A0 (en) | Anti-ly6e antibodies and methods of use | |
| EP2961765A4 (en) | SMALL MOLECULAR PCSK9 MODULATORS AND METHOD OF USE THEREOF | |
| PT2994150T (pt) | Probióticos e métodos de utilização | |
| IL240505A0 (en) | Accumulations of lanthanides and methods for their use | |
| ZA201600856B (en) | Protein tyrosine kinase modulators and methods of use | |
| IL242818B (en) | Il-1beta-il-1ra chimera and methods of using the same |